[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correction
July 2007

Incorrect Dose in: Randomized Double-blind Trial of Treatment of Vitiligo: Efficacy of Psoralen–UV-A Therapy vs Narrowband–UV-B Therapy

Arch Dermatol. 2007;143(7):906. doi:10.1001/archderm.143.7.906

Incorrect Dose. In the Study titled “Randomized Double-blind Trial of Treatment of Vitiligo: Efficacy of Psoralen–UV-A Therapy vs Narrowband–UV-B Therapy” by Yones et al, published in the May issue of the Archives (2007;143[5]:578-584), the dose for 5-methoxypsoralen was incorrectly reported. On page 579, left-hand column, “Administration of Oral Psoralen or Placebo” subsection of the “Methods” section, the last sentence should have read as follows: “During the course of the study, patients intolerant of 8-MOP because of nausea instead were given identical-appearing 5-methoxypsoralen (5-MOP) tablets (20-mg Pentaderm tablets; Crawford Pharmaceuticals Ltd) at a dose of 50 mg/m2 (range, 60-80 mg) 3 hours before phototherapy.” This article was corrected online prior to publication of the correction in print.

First Page Preview View Large
First page PDF preview
First page PDF preview
×